

Title (en)
EPITOPES OR MIMOTOPES DERIVED FROM THE C-EPSILON-2 DOMAIN OF IGE, ANTAGONISTS THEROF, AND THEIR THERAPEUTIC USES

Title (de)
EPITOPE UND MIMOTOPE ABSTAMMEND VON DER C-EPSILON-2 DOMÄNE VON IGE, DEREN ANTAGONISTEN, UND DEREN THERAPEUTISCHE VERWENDUNGEN

Title (fr)
EPITOPES OU MIMOTOPES DERIVES DU DOMAINE C-EPSILON-2 DE L'IMMOGLOBULINE E, LEURS ANTAGONISTES ET LEURS APPLICATIONS THERAPEUTIQUES

Publication
EP 1155037 A1 20011121 (EN)

Application
EP 00905073 A 20000222

Priority

- EP 0001455 W 20000222
- GB 9904405 A 19990225
- GB 9907151 A 19990329
- GB 9910537 A 19990507
- GB 9910538 A 19990507
- GB 9918594 A 19990807
- GB 9918603 A 19990807
- GB 9921046 A 19990907
- GB 9921047 A 19990907
- GB 9925619 A 19991029
- GB 9927698 A 19991123

Abstract (en)
[origin: WO0050460A1] The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are isolated peptides incorporating epitopes or mimotopes of surface exposed regions of the C epsilon 2 domain of IgE. The inventors have found that these novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the surface exposed IgE regions of the present invention, and their use in medicine as passive immunotherapy or in immunoprophylaxis.

IPC 1-7
C07K 16/00; **C07K 16/42**; **A61K 39/00**; **A61K 39/385**; **A61K 39/395**; **G01N 33/577**; **G01N 33/68**; **A61P 37/08**

IPC 8 full level
A61K 38/00 (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 47/48** (2006.01); **A61P 31/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/08** (2006.01); **B01J 20/281** (2006.01); **G01N 33/53** (2006.01); **C07K 7/00** (2006.01); **C07K 14/02** (2006.01); **C07K 16/00** (2006.01); **C07K 16/42** (2006.01); **C07K 19/00** (2006.01); **G01N 30/88** (2006.01)

CPC (source: EP KR)
A61K 47/6425 (2017.08 - EP); **A61K 47/646** (2017.08 - EP); **A61P 31/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **C07K 14/47** (2013.01 - KR); **C07K 16/00** (2013.01 - EP); **C07K 16/4291** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **A61K 2039/6068** (2013.01 - EP); **C07K 2317/52** (2013.01 - EP)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0050460 A1 20000831; AR 029336 A1 20030625; AU 2672700 A 20000914; BR 0008963 A 20011127; CA 2363637 A1 20000831; CN 1348466 A 20020508; CO 5210906 A1 20021030; CZ 20013082 A3 20020213; EP 1155037 A1 20011121; HK 1044004 A1 20021004; HU P0200049 A2 20020529; IL 145024 A0 20020630; JP 2004538238 A 20041224; KR 20020007313 A 20020126; MX PA01008613 A 20030624; NO 20014130 D0 20010824; NO 20014130 L 20010913; NZ 513679 A 20010928; PL 350993 A1 20030224; TR 200102506 T2 20020621

DOCDB simple family (application)
EP 0001455 W 20000222; AR P000100820 A 20000225; AU 2672700 A 20000222; BR 0008963 A 20000222; CA 2363637 A 20000222; CN 00806614 A 20000222; CO 00013394 A 20000225; CZ 20013082 A 20000222; EP 00905073 A 20000222; HK 02103724 A 20020516; HU P0200049 A 20000222; IL 14502400 A 20000222; JP 2000601038 A 20000222; KR 20017010939 A 20010825; MX PA01008613 A 20000222; NO 20014130 A 20010824; NZ 51367900 A 20000222; PL 35099300 A 20000222; TR 200102506 T 20000222